MedTrace Logo

Study on Anti-inflammatory Effects of Topical R115866 Gel

NCT00719121 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-09-26

No results posted yet for this study

Summary

The purpose of this exploratory trial is to assess the anti-inflammatory effect(s) of topical R115866 in a model of UVB-induced inflammation and in a model of cutaneous irritation.

Conditions

  • Cutaneous Inflammation

Interventions

DRUG

Talarozole

Topical Application (20 mg)

DRUG

Differin™, 0.1% adapalene gel

Topical Application (20 mg)

Sponsors & Collaborators

  • Stiefel, a GSK Company

    lead INDUSTRY

Principal Investigators

  • Prof. Dr. G. Piérard, MD, PhD · Department of Dermatopathology Centre Hospitalier Universitaire du Sart-Tilman

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2006-12-31
Completion
2007-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00719121 on ClinicalTrials.gov